CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression

Documenti analoghi

• Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
  di: Yoo Jin Jang, et al.
  Pubblicazione: (2024)
• Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
  di: Aiden‐Hung P. Nguyen, et al.
  Pubblicazione: (2026)
• Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus)
  di: Michael D. Kleinhenz, et al.
  Pubblicazione: (2024)
• Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
  di: Peile Wang, et al.
  Pubblicazione: (2024)
• Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
  di: Yi‐An Bi, et al.
  Pubblicazione: (2024)